peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Increase of number of shares and votes in Hansa Medical AB (publ)

31 May 2017, 08:00
Regulatory information
As previously announced, the board of directors of Hansa Medical AB (publ) has on 26 April 2017, by virtue of authorization by the general meeting on 21 November 2016, resolved on a share issue of 401,000 class C shares. The company’s registered share capital and number of outstanding shares and votes have thus increased during May 2017.

All class C shares are owned by the company. The share issue forms part of the company’s long term incentive program. Prior to delivery of shares to qualifying participants at the end of the program, class C shares will be converted to ordinary shares.

As of May 31, 2017, the total number of registered and outstanding shares of Hansa Medical amounts to 35,455,860 of which 35,054,860 are ordinary shares, with one vote per share, and 401,000 are class C shares, with one tenth of a vote per share. As of May 31, 2017, the number of votes in Hansa Medical amounts to 35,094,960 and the registered share capital amounts to SEK 35,455,860.  

This information is information that Hansa Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act.The information was submitted for publication, through the agency of the contact person set out below, at 08:00 am CEST on 31 May 2017.

For further information, please contact:
Hansa Medical AB
Göran Arvidson, CEO
Mobile: +46 70-633 30 42

About Hansa Medical AB
Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The lead project IdeS is a proprietary antibodydegrading enzyme currently in late- stage clinical development for kidney transplant patients, with significant potential for further development in other solid organ transplants and a wide range of acute autoimmune indications. The company also has a strong pipeline of preclinical assets that may provide a second wave of potential drugs. Under the project name NiceR, novel immunoglobulin cleaving enzymes are developed for repeat dosing translating the Hansa Medical technology into relapsing autoimmune diseases and oncology. Hansa Medical is based in Lund, Sweden, its shares (ticker: HMED) are listed on Nasdaq Stockholm.